LGND Quote, Financials, Valuation and Earnings

Alnylam Pharmaceuticals, Inc. has a net margin of 10.18% compared to Ligand Pharmaceuticals, Inc.'s net margin of 20.1%. Ligand Pharmaceuticals, Inc.'s return on equity of 5.72% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 31.15%.

Ligand Pharmaceuticals, Inc. has a consensus price target of $237.50, signalling upside risk potential of 26%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $492.17 which suggests that it could grow by 5.77%. Given that Ligand Pharmaceuticals, Inc. has higher upside potential than Alnylam Pharmaceuticals, Inc., analysts believe Ligand Pharmaceuticals, Inc. is more attractive than Alnylam Pharmaceuticals, Inc..

Ligand Pharmaceuticals, Inc. has a beta of 1.026, which suggesting that the stock is 2.587% more volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.301, suggesting its less volatile than the S&P 500 by 69.879%.

Ligand Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ligand Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Ligand Pharmaceuticals, Inc. quarterly revenues are $115.5M, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.2B. Ligand Pharmaceuticals, Inc.'s net income of $117.3M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $251.1M. Notably, Ligand Pharmaceuticals, Inc.'s price-to-earnings ratio is 90.73x while Alnylam Pharmaceuticals, Inc.'s PE ratio is 1,934.89x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ligand Pharmaceuticals, Inc. is 14.77x versus 19.09x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Merck & Co., Inc. has a net margin of 10.18% compared to Ligand Pharmaceuticals, Inc.'s net margin of 33.68%. Ligand Pharmaceuticals, Inc.'s return on equity of 5.72% beat Merck & Co., Inc.'s return on equity of 39.63%.

Ligand Pharmaceuticals, Inc. has a consensus price target of $237.50, signalling upside risk potential of 26%. On the other hand Merck & Co., Inc. has an analysts' consensus of $105.92 which suggests that it could grow by 4.99%. Given that Ligand Pharmaceuticals, Inc. has higher upside potential than Merck & Co., Inc., analysts believe Ligand Pharmaceuticals, Inc. is more attractive than Merck & Co., Inc..

Ligand Pharmaceuticals, Inc. has a beta of 1.026, which suggesting that the stock is 2.587% more volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.294, suggesting its less volatile than the S&P 500 by 70.604%.

Ligand Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & Co., Inc. offers a yield of 3.21% to investors and pays a quarterly dividend of $0.81 per share. Ligand Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Merck & Co., Inc. pays out 46.32% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Ligand Pharmaceuticals, Inc. quarterly revenues are $115.5M, which are smaller than Merck & Co., Inc. quarterly revenues of $17.2B. Ligand Pharmaceuticals, Inc.'s net income of $117.3M is lower than Merck & Co., Inc.'s net income of $5.8B. Notably, Ligand Pharmaceuticals, Inc.'s price-to-earnings ratio is 90.73x while Merck & Co., Inc.'s PE ratio is 13.35x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ligand Pharmaceuticals, Inc. is 14.77x versus 3.98x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals, Inc. has a net margin of 10.18% compared to Ligand Pharmaceuticals, Inc.'s net margin of -255.85%. Ligand Pharmaceuticals, Inc.'s return on equity of 5.72% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.

Ligand Pharmaceuticals, Inc. has a consensus price target of $237.50, signalling upside risk potential of 26%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -22.02%. Given that Ligand Pharmaceuticals, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Ligand Pharmaceuticals, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..

Ligand Pharmaceuticals, Inc. has a beta of 1.026, which suggesting that the stock is 2.587% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.

Ligand Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Ligand Pharmaceuticals, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Ligand Pharmaceuticals, Inc. quarterly revenues are $115.5M, which are larger than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Ligand Pharmaceuticals, Inc.'s net income of $117.3M is higher than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Ligand Pharmaceuticals, Inc.'s price-to-earnings ratio is 90.73x while NovaBay Pharmaceuticals, Inc.'s PE ratio is 1.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ligand Pharmaceuticals, Inc. is 14.77x versus 2.12x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of 10.18% compared to Ligand Pharmaceuticals, Inc.'s net margin of --. Ligand Pharmaceuticals, Inc.'s return on equity of 5.72% beat Palatin Technologies's return on equity of --.

Ligand Pharmaceuticals, Inc. has a consensus price target of $237.50, signalling upside risk potential of 26%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Ligand Pharmaceuticals, Inc., analysts believe Palatin Technologies is more attractive than Ligand Pharmaceuticals, Inc..

Ligand Pharmaceuticals, Inc. has a beta of 1.026, which suggesting that the stock is 2.587% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.

Ligand Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ligand Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Ligand Pharmaceuticals, Inc. quarterly revenues are $115.5M, which are larger than Palatin Technologies quarterly revenues of --. Ligand Pharmaceuticals, Inc.'s net income of $117.3M is higher than Palatin Technologies's net income of --. Notably, Ligand Pharmaceuticals, Inc.'s price-to-earnings ratio is 90.73x while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ligand Pharmaceuticals, Inc. is 14.77x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.